The Valley Desk

NCT00267748 · Interventional trial

Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)

Overall registry status Completed

Phase 2

Conditions Carcinoma, Renal Cell

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov